Mechanism of action of nadofaragene firadenovec-vncg
Effective bladder-preserving therapeutic options are needed for patients with bacillus Calmette-Guérin unresponsive non–muscle-invasive bladder cancer. Nadofaragene firadenovec-vncg (Adstiladrin®) was approved by the US Food and Drug Administration as the first gene therapy in urology and the first...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2024-03-01
|
| Reeks: | Frontiers in Oncology |
| Onderwerpen: | |
| Online toegang: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1359725/full |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|